375 related articles for article (PubMed ID: 29114469)
21. Molecular Subtypes of Pulmonary Large-cell Neuroendocrine Carcinoma Predict Chemotherapy Treatment Outcome.
Derks JL; Leblay N; Thunnissen E; van Suylen RJ; den Bakker M; Groen HJM; Smit EF; Damhuis R; van den Broek EC; Charbrier A; Foll M; McKay JD; Fernandez-Cuesta L; Speel EM; Dingemans AC;
Clin Cancer Res; 2018 Jan; 24(1):33-42. PubMed ID: 29066508
[No Abstract] [Full Text] [Related]
22. High grade neuroendocrine lung tumors: pathological characteristics, surgical management and prognostic implications.
Grand B; Cazes A; Mordant P; Foucault C; Dujon A; Guillevin EF; Barthes FLP; Riquet M
Lung Cancer; 2013 Sep; 81(3):404-409. PubMed ID: 23769675
[TBL] [Abstract][Full Text] [Related]
23. Different Characteristics and Survival between Surgically Resected Pure and Combined Pulmonary Large Cell Neuroendocrine Carcinoma.
Wang Y; Chen Y; Yang Z; Qian F; Hu M; Lu J; Zhang Y; Zhang W; Wang K; Han B
Ann Surg Oncol; 2022 Sep; 29(9):5666-5678. PubMed ID: 35543906
[TBL] [Abstract][Full Text] [Related]
24. [Pulmonary neuroendocrine tumors in the new WHO 2015 classification: Start of breaking new grounds?].
Schnabel PA; Junker K
Pathologe; 2015 May; 36(3):283-92. PubMed ID: 25956813
[TBL] [Abstract][Full Text] [Related]
25. Therapeutic strategies and genetic profile comparisons in small cell carcinoma and large cell neuroendocrine carcinoma of the lung using next-generation sequencing.
Ito M; Miyata Y; Hirano S; Kimura S; Irisuna F; Ikeda K; Kushitani K; Tsutani Y; Ueda D; Tsubokawa N; Takeshima Y; Okada M
Oncotarget; 2017 Dec; 8(65):108936-108945. PubMed ID: 29312580
[TBL] [Abstract][Full Text] [Related]
26. Comparison of genomic landscapes of large cell neuroendocrine carcinoma, small cell lung carcinoma, and large cell carcinoma.
Zhou Z; Zhu L; Niu X; Shen S; Zhao Y; Zhang J; Ye J; Han-Zhang H; Liu J; Liu C; Lu S
Thorac Cancer; 2019 Apr; 10(4):839-847. PubMed ID: 30793508
[TBL] [Abstract][Full Text] [Related]
27. Novel Mouse Cell Lines and In Vivo Models for Human High-Grade Neuroendocrine Lung Carcinoma, Small Cell Lung Carcinoma (SCLC), and Large Cell Neuroendocrine Carcinoma (LCNEC).
Recuero E; Lázaro S; Lorz C; Enguita AB; Garcia-Escudero R; Santos M
Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37894963
[TBL] [Abstract][Full Text] [Related]
28. POU2F3-Expressing Small Cell Lung Carcinoma and Large Cell Neuroendocrine Carcinoma Show Morphologic and Phenotypic Overlap.
Jimbo N; Ohbayashi C; Takeda M; Fujii T; Mitsui S; Tsukamoto R; Tanaka Y; Itoh T; Maniwa Y
Am J Surg Pathol; 2024 Jan; 48(1):4-15. PubMed ID: 37904277
[TBL] [Abstract][Full Text] [Related]
29. Clinical features and treatment outcomes of resected large cell neuroendocrine carcinoma of the lung.
Moon JY; Choi SH; Kim TH; Lee J; Pyo JH; Kim YT; Lee SJ; Yoon HI; Cho J; Lee CG
Radiat Oncol J; 2021 Dec; 39(4):288-296. PubMed ID: 34986550
[TBL] [Abstract][Full Text] [Related]
30. Large cell neuroendocrine carcinoma of the lung: a histologic and immunohistochemical study of 22 cases.
Jiang SX; Kameya T; Shoji M; Dobashi Y; Shinada J; Yoshimura H
Am J Surg Pathol; 1998 May; 22(5):526-37. PubMed ID: 9591721
[TBL] [Abstract][Full Text] [Related]
31. Chromosomal aberrations in a series of large-cell neuroendocrine carcinomas: unexpected divergence from small-cell carcinoma of the lung.
Ullmann R; Petzmann S; Sharma A; Cagle PT; Popper HH
Hum Pathol; 2001 Oct; 32(10):1059-63. PubMed ID: 11679939
[TBL] [Abstract][Full Text] [Related]
32. Comparison of four DLL3 antibodies performance in high grade neuroendocrine lung tumor samples and cell cultures.
Brcic L; Kuchler C; Eidenhammer S; Pabst D; Quehenberger F; Gazdar AF; Popper H
Diagn Pathol; 2019 May; 14(1):47. PubMed ID: 31109352
[TBL] [Abstract][Full Text] [Related]
33. High-grade neuroendocrine carcinoma of the lung: comparative clinicopathological study of large cell neuroendocrine carcinoma and small cell lung carcinoma.
Sun L; Sakurai S; Sano T; Hironaka M; Kawashima O; Nakajima T
Pathol Int; 2009 Aug; 59(8):522-9. PubMed ID: 19627535
[TBL] [Abstract][Full Text] [Related]
34. Systemic treatment for neuroendocrine non-small cell lung carcinoma: A cases series and a systematic review of the literature.
Jelli B; Brandão M; Mekinda Z; Durieux V; Berghmans T
Lung Cancer; 2023 Jul; 181():107232. PubMed ID: 37216840
[TBL] [Abstract][Full Text] [Related]
35. Large cell neuroendocrine carcinoma with a solitary brain metastasis and low Ki-67: a unique subtype.
Hermans BCM; Derks JL; Groen HJM; Stigt JA; van Suylen RJ; Hillen LM; van den Broek EC; Speel EJM; Dingemans AC
Endocr Connect; 2019 Dec; 8(12):1600-1606. PubMed ID: 31751303
[TBL] [Abstract][Full Text] [Related]
36. [Clinical and molecular pathological features of bronchopulmonary large cell neuroendocrine carcinoma].
Meng Y; Lian YB; Xu Y; Dong JQ; Song M
Zhonghua Yi Xue Za Zhi; 2022 Apr; 102(14):1020-1027. PubMed ID: 35399022
[No Abstract] [Full Text] [Related]
37. Molecular Pathology of Pulmonary Large Cell Neuroendocrine Carcinoma: Novel Concepts and Treatments.
Yoshimura M; Seki K; Bychkov A; Fukuoka J
Front Oncol; 2021; 11():671799. PubMed ID: 33968782
[TBL] [Abstract][Full Text] [Related]
38. Characteristics of loss of heterozygosity in large cell neuroendocrine carcinomas of the lung and small cell lung carcinomas.
Takeuchi T; Minami Y; Iijima T; Kameya T; Asamura H; Noguchi M
Pathol Int; 2006 Aug; 56(8):434-9. PubMed ID: 16872437
[TBL] [Abstract][Full Text] [Related]
39. Targeting ALK in Neuroendocrine Tumors of the Lung.
Akhoundova D; Haberecker M; Fritsch R; Höller S; Kiessling MK; Rechsteiner M; Rüschoff JH; Curioni-Fontecedro A
Front Oncol; 2022; 12():911294. PubMed ID: 35756632
[TBL] [Abstract][Full Text] [Related]
40. Does subtyping of high-grade pulmonary neuroendocrine carcinomas have an impact on therapy selection?
Popper H; Brcic L; Eidenhammer S
Transl Lung Cancer Res; 2023 Dec; 12(12):2412-2426. PubMed ID: 38205203
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
